Centre Hospitalier Lyon Sud

Pierre-Bénite, France

33 recruiting

Showing 120 of 57 trials

Recruiting
Phase 3

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

Metabolic Dysfunction-Associated Steatohepatitis
Boehringer Ingelheim1,590 enrolled444 locationsNCT06632457
Recruiting
Phase 3

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

Metabolic dysfunction-associated steatohepatitis (MASH)Liver Fibrosis
Boehringer Ingelheim1,800 enrolled525 locationsNCT06632444
Recruiting
Phase 1Phase 2

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaMixed Phenotype Acute Leukemia+2 more
Syndax Pharmaceuticals447 enrolled57 locationsNCT04065399
Recruiting

Computerized Registry of Patients With Venous Thromboembolism (RIETE)

Venous Thromboembolism
Manuel Monreal120,000 enrolled257 locationsNCT02832245
Recruiting
Phase 3

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Relapsed or Refractory Multiple Myeloma (RRMM)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company440 enrolled141 locationsNCT06615479
Recruiting
Phase 3

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

Obesity or Overweight
Hoffmann-La Roche2,000 enrolled164 locationsNCT07351045
Recruiting
Phase 3

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Non-small Cell Lung Cancer
Bristol-Myers Squibb1,000 enrolled320 locationsNCT06561386
Recruiting
Phase 2

Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)

InfectionsAcute Respiratory Distress Syndrome
BioAegis Therapeutics Inc.600 enrolled70 locationsNCT05947955
Recruiting

EORTC Metastatic Breast Cancer Module Development

Metastatic Beast Cancer
University of Leeds568 enrolledNCT07806266
Recruiting
Phase 3

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

Metabolic Dysfunction-Associated Steatotic Liver Disease
Eli Lilly and Company4,500 enrolled563 locationsNCT07165028
Recruiting
Phase 2

LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis (UC)Ulcerative Colitis, Active ModerateUlcerative Colitis, Active Severe
Eli Lilly and Company1,431 enrolled258 locationsNCT07415044
Recruiting
Phase 3

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

Urinary Bladder NeoplasmsNeoplasm MetastasisCarcinoma, Transitional Cell
Eli Lilly and Company450 enrolled286 locationsNCT07218380
Recruiting
Phase 3

A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

MyelofibrosisAnemia
Takeda324 enrolled207 locationsNCT07623161
Recruiting
Phase 3

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

Metastatic Castration-resistant Prostate Cancer
Pfizer900 enrolled237 locationsNCT06629779
Recruiting
Phase 3

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer
Celgene960 enrolled281 locationsNCT06764485
Recruiting
Phase 3

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaLeukemia, B-cell+1 more
Loxo Oncology, Inc.737 enrolled143 locationsNCT05254743
Recruiting
Phase 3

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

Prostate CancerCancer of the ProstateHormone Sensitive Prostate Cancer+1 more
Pfizer1,000 enrolled341 locationsNCT07028853
Recruiting
Phase 3

Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients

Multiple Myeloma, Newly Diagnosed
Intergroupe Francophone du Myelome824 enrolled64 locationsNCT06918002
Recruiting
Phase 1Phase 2

A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

Myelofibrosis
Sumitomo Pharma America, Inc.240 enrolled84 locationsNCT04176198
Recruiting
Phase 2

Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment

Malignant Solid Neoplasms
Centre Leon Berard900 enrolled7 locationsNCT02029001